Aranesp, Procrit Face New Headwind With Tumor-Specific Restrictions
Executive Summary
The sponsors of erythropoiesis-stimulating agents are hoping FDA will make its next round of label updates for the anemia therapies based on the totality of clinical data rather than clinical trials evaluating Amgen's Aranesp (epoetin alfa) and Johnson & Johnson's Procrit (darbepoetin alfa) in specific cancers